These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

668 related articles for article (PubMed ID: 26517678)

  • 1. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
    Kim A; Seong KM; Kang HJ; Park S; Lee SS
    Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736.
    Restelli V; Chilà R; Lupi M; Rinaldi A; Kwee I; Bertoni F; Damia G; Carrassa L
    Oncotarget; 2015 Nov; 6(35):37229-40. PubMed ID: 26439697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The preclinical discovery and development of bortezomib for the treatment of mantle cell lymphoma.
    Arkwright R; Pham TM; Zonder JA; Dou QP
    Expert Opin Drug Discov; 2017 Feb; 12(2):225-235. PubMed ID: 27917682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arsenic trioxide rewires mantle cell lymphoma response to bortezomib.
    Zhao LL; Liu YF; Peng LJ; Fei AM; Cui W; Miao SC; Hermine O; Gressin R; Khochbin S; Chen SJ; Wang J; Mi JQ
    Cancer Med; 2015 Nov; 4(11):1754-66. PubMed ID: 26310857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma.
    Xargay-Torrent S; López-Guerra M; Montraveta A; Saborit-Villarroya I; Rosich L; Navarro A; Pérez-Galán P; Roué G; Campo E; Colomer D
    Clin Cancer Res; 2013 Feb; 19(3):586-97. PubMed ID: 23231952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effects of the phosphoinostitide-3'-kinase delta inhibitor, CAL-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism].
    Qu F; Xia B; Li X; Guo S; Zhang L; Tian C; Yu Y; Zhang Y
    Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):412-7. PubMed ID: 26463142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma.
    Gonzalez-Santamarta M; Quinet G; Reyes-Garau D; Sola B; Roué G; Rodriguez MS
    Adv Exp Med Biol; 2020; 1233():153-174. PubMed ID: 32274756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo.
    Sun L; Zhang L; Qian J; Yang J; Yi Q; Dong W; Wang M
    Leuk Res; 2012 Mar; 36(3):363-8. PubMed ID: 22000823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells.
    Kim A; Park S; Lee JE; Jang WS; Lee SJ; Kang HJ; Lee SS
    Leuk Res; 2012 Jul; 36(7):912-20. PubMed ID: 22560334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reactive oxygen species mediate cancer stem-like cells and determine bortezomib sensitivity via Mcl-1 and Zeb-1 in mantle cell lymphoma.
    Luanpitpong S; Poohadsuan J; Samart P; Kiratipaiboon C; Rojanasakul Y; Issaragrisil S
    Biochim Biophys Acta Mol Basis Dis; 2018 Nov; 1864(11):3739-3753. PubMed ID: 30251692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bcl-2 Family Members Bcl-xL and Bax Cooperatively Contribute to Bortezomib Resistance in Mantle Cell Lymphoma.
    Luanpitpong S; Janan M; Yosudjai J; Poohadsuan J; Chanvorachote P; Issaragrisil S
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms.
    Nguyen T; Parker R; Zhang Y; Hawkins E; Kmieciak M; Craun W; Grant S
    BMC Cancer; 2018 Nov; 18(1):1129. PubMed ID: 30445933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
    Dasmahapatra G; Patel H; Dent P; Fisher RI; Friedberg J; Grant S
    Br J Haematol; 2013 Apr; 161(1):43-56. PubMed ID: 23360303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD19 amplifies B lymphocyte signal transduction by regulating Src-family protein tyrosine kinase activation.
    Fujimoto M; Poe JC; Jansen PJ; Sato S; Tedder TF
    J Immunol; 1999 Jun; 162(12):7088-94. PubMed ID: 10358152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the PI3K/Akt/mTOR signaling pathway by pterostilbene attenuates mantle cell lymphoma progression.
    Yu D; Zhang Y; Chen G; Xie Y; Xu Z; Chang S; Hu L; Li B; Bu W; Wang Y; Xiao W; Sun X; Chang G; Gao L; Qiang S; Wu X; Zhu W; Shi J
    Acta Biochim Biophys Sin (Shanghai); 2018 Aug; 50(8):782-792. PubMed ID: 29961897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.
    Franke NE; Kaspers GL; Assaraf YG; van Meerloo J; Niewerth D; Kessler FL; Poddighe PJ; Kole J; Smeets SJ; Ylstra B; Bi C; Chng WJ; Horton TM; Menezes RX; Musters RJ; Zweegman S; Jansen G; Cloos J
    Oncotarget; 2016 Nov; 7(46):74779-74796. PubMed ID: 27542283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Autophagic degradation of NOXA underlies stromal cell-mediated resistance to proteasome inhibitors in mantle cell lymphoma.
    Kuroda Y; Koyama D; Kikuchi J; Mori S; Ichinohe T; Furukawa Y
    Leuk Res; 2021 Dec; 111():106672. PubMed ID: 34332177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
    Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
    Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.
    Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L
    Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines.
    Shirsath NP; Manohar SM; Joshi KS
    Mol Cancer; 2012 Oct; 11():77. PubMed ID: 23075291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.